Milanese C, Salmaggi A, La Mantia L, Campi A, Eoli M, Savoiardo M, Bianchi G, Nespolo A
Department of Neurology, Istituto Neurologico C Besta, Milan, Italy.
J Neurol Neurosurg Psychiatry. 1990 Jul;53(7):554-7. doi: 10.1136/jnnp.53.7.554.
Sixteen patients with clinically definite MS admitted to a double blind randomised controlled trial of intrathecal natural beta-IFN were followed for a mean of 22 months including the six month treatment period. Clinical response, evaluated in terms of relapse frequency and of progression rate, showed an increase in relapse rate in treated patients during the six month treatment period and, overall, no benefit in treated versus placebo patients. Serial evaluations were made of cerebrospinal fluid (CSF) cells, IgG, myelin basic protein and CSF and blood T-cell subsets. A rise in CSF IgG Index, MBP and DR+ cells in IFN-treated patients suggested an activation of intrathecal immune response in treated patients.
16名临床确诊为多发性硬化症的患者参加了一项鞘内注射天然β-干扰素的双盲随机对照试验，随访时间平均为22个月，包括6个月的治疗期。根据复发频率和进展速度评估的临床反应显示，在6个月的治疗期内，治疗组患者的复发率有所增加，总体而言，治疗组与安慰剂组患者相比并无益处。对脑脊液（CSF）细胞、免疫球蛋白G（IgG）、髓鞘碱性蛋白（MBP）以及脑脊液和血液中的T细胞亚群进行了系列评估。干扰素治疗组患者脑脊液中的IgG指数、MBP和DR+细胞升高，提示治疗组患者鞘内免疫反应被激活。
